147 related articles for article (PubMed ID: 34907652)
1. Safety and response after peptide receptor radionuclide therapy with
Kudo A; Tateishi U; Yoshimura R; Tsuchiya J; Yokoyama K; Takano S; Kobayashi N; Utsunomiya D; Hata M; Ichikawa Y; Tanabe M; Hosono M; Kinuya S
J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):487-499. PubMed ID: 34907652
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of peptide receptor radionuclide therapy with
Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y
Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700
[TBL] [Abstract][Full Text] [Related]
3. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of
Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry and pharmacokinetics of [
Schürrle SB; Eberlein U; Ansquer C; Beauregard JM; Durand-Gasselin L; Grønbæk H; Haug A; Hicks RJ; Lenzo NP; Navalkissoor S; Nicolas GP; Pais B; Volteau M; Wild D; McEwan A; Lassmann M
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2428-2441. PubMed ID: 38528164
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Lutetium [
Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
[TBL] [Abstract][Full Text] [Related]
8. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
9. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
10. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
[TBL] [Abstract][Full Text] [Related]
11.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
12. Survival predictors of
Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 Trial of
Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based
Sundlöv A; Gleisner KS; Tennvall J; Ljungberg M; Warfvinge CF; Holgersson K; Hallqvist A; Bernhardt P; Svensson J
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3830-3840. PubMed ID: 35451612
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.
Fröss-Baron K; Garske-Roman U; Welin S; Granberg D; Eriksson B; Khan T; Sandström M; Sundin A
Neuroendocrinology; 2021; 111(4):330-343. PubMed ID: 32097917
[TBL] [Abstract][Full Text] [Related]
17. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of
Clement D; Navalkissoor S; Srirajaskanthan R; Courbon F; Dierickx L; Eccles A; Lewington V; Mitjavila M; Percovich JC; Lequoy B; He B; Folitar I; Ramage J
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3529-3537. PubMed ID: 35389069
[TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children.
Foster JH; Sher A; Seghers V; Poston J; Wells D; Delpassand ES; Potter S; Mahajan P; Venkatramani R
Pediatr Blood Cancer; 2021 Jul; 68(7):e29056. PubMed ID: 33844446
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of the safety and efficacy of [
Wild D; Grønbæk H; Navalkissoor S; Haug A; Nicolas GP; Pais B; Ansquer C; Beauregard JM; McEwan A; Lassmann M; Pennestri D; Volteau M; Lenzo NP; Hicks RJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):183-195. PubMed ID: 37721581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
